Stock Research: Novartis

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Novartis

SWX:NOVN CH0012005267
25
  • Value
    23
  • Growth
    71
  • Safety
    Safety
    34
  • Combined
    29
  • Sentiment
    44
  • 360° View
    360° View
    25
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Novartis AG is a pharmaceutical company that develops and markets branded and generic prescription drugs. It operates in the pharmaceutical industry, with focus on immunology, dermatology, cancer, and more. Novartis operates globally, with a strong presence in Switzerland. In the last fiscal year, the company had a market cap of $253,332 million, profits of $38,907 million, revenue of $51,722 million, and 75883 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 25 (better than 25% compared with alternatives), overall professional sentiment and financial characteristics for the stock Novartis are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Novartis. The consolidated Growth Rank has a good rank of 71, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 71% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 34 means that the share price of Novartis is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 66% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 23, which means that the company has a riskier financing structure than 77% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 44, indicating professional investors are more pessimistic about the stock than for 56% of alternative investment opportunities. ...read more

more
Index
Dividends Europe
Diversity Europe
Moonshot Tech
SPI
SMI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
34 42 53 74
Growth
71 28 25 39
Safety
Safety
23 9 22 10
Sentiment
44 74 84 68
360° View
360° View
25 17 37 36
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
11 13 34 33
Opinions Change
45 82 87 49
Pro Holdings
n/a 81 70 92
Market Pulse
85 69 61 47
Sentiment
44 74 84 68
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
34 42 53 74
Growth
71 28 25 39
Safety Safety
23 9 22 10
Combined
29 1 8 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
58 60 59 75
Price vs. Earnings (P/E)
17 18 24 48
Price vs. Book (P/B)
12 17 26 55
Dividend Yield
76 85 90 90
Value
34 42 53 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
28 14 6 26
Profit Growth
66 39 48 43
Capital Growth
84 47 31 63
Stock Returns
65 64 62 52
Growth
71 28 25 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
24 25 40 19
Refinancing
13 13 9 1
Liquidity
62 59 55 54
Safety Safety
23 9 22 10

Similar Stocks

Discover high‑ranked alternatives to Novartis and broaden your portfolio horizons.

Ipsen

ENXTPA:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

SoftwareONE Holding

SWX:SWON
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.